Sign In

Login

Password

Forgot Password ? Sign Up

Pagoclon (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pagoclon" in German language version.

refsWebsite
Global rank German rank
7doi.org
2nd place
3rd place
5nih.gov
4th place
7th place
1patents.google.com
1,182nd place
6,586th place

doi.org

  • Lingford-Hughes A., S. J. Wilson, A. Feeney, P. G. Grasby, D. J. Nutt: A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. In: Psychopharmacology. 180. Jahrgang, Nr. 4, 2005, S. 1–3, doi:10.1007/s00213-005-0060-1, PMID 15986186.
  • Atack J. R., Pike A., Marshall G., Stanley J., Lincoln R., Cook S. M., Lewis R. T., Blackaby W. P., Goodacre S. C., McKernan R. M., Dawson G. R., Wafford K. A., Reynolds D. S.: The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone. In: Neuropharmacology. 50. Jahrgang, Nr. 6, 2006, S. 677–89, doi:10.1016/j.neuropharm.2005.11.014, PMID 16430927.
  • J. R. Atack: The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. In: Expert Opinion on Investigational Drugs. 14. Jahrgang, Nr. 5, Mai 2005, S. 601–18, doi:10.1517/13543784.14.5.601, PMID 15926867.
  • J. R. Atack: Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. In: Current Drug Targets. CNS and Neurological Disorders. 2. Jahrgang, Nr. 4, August 2003, S. 213–32, doi:10.2174/1568007033482841, PMID 12871032.
  • D. J. Nutt: Alcohol alternatives – a goal for psychopharmacology? In: J Psychopharmacol. Band 20, Nr. 3, Mai 2006, S. 327-8, doi:10.1177/0269881106063042.
  • G. Maguire, D. Franklin, N. G. Vatakis, E. Morgenshtern, T. Denko, J. S. Yaruss, C. Spotts, L. Davis, A. Davis, P. Fox, P. Soni, M. Blomgren, A. Silverman, G. Riley: Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pagoclon for peRsistent dEvelopmental Stuttering Study. In: Journal of Clinical Psychopharmacology. 30. Jahrgang, Nr. 1, Februar 2010, S. 48–56, doi:10.1097/jcp.0b013e3181caebbe, PMID 20075648.
  • J. J. Sandford et al.: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. In: J Psychopharmacol. Band 15, Nr. 3, September 2001, doi:10.1177/026988110101500312.

nih.gov

ncbi.nlm.nih.gov

  • Lingford-Hughes A., S. J. Wilson, A. Feeney, P. G. Grasby, D. J. Nutt: A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. In: Psychopharmacology. 180. Jahrgang, Nr. 4, 2005, S. 1–3, doi:10.1007/s00213-005-0060-1, PMID 15986186.
  • Atack J. R., Pike A., Marshall G., Stanley J., Lincoln R., Cook S. M., Lewis R. T., Blackaby W. P., Goodacre S. C., McKernan R. M., Dawson G. R., Wafford K. A., Reynolds D. S.: The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone. In: Neuropharmacology. 50. Jahrgang, Nr. 6, 2006, S. 677–89, doi:10.1016/j.neuropharm.2005.11.014, PMID 16430927.
  • J. R. Atack: The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. In: Expert Opinion on Investigational Drugs. 14. Jahrgang, Nr. 5, Mai 2005, S. 601–18, doi:10.1517/13543784.14.5.601, PMID 15926867.
  • J. R. Atack: Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. In: Current Drug Targets. CNS and Neurological Disorders. 2. Jahrgang, Nr. 4, August 2003, S. 213–32, doi:10.2174/1568007033482841, PMID 12871032.
  • G. Maguire, D. Franklin, N. G. Vatakis, E. Morgenshtern, T. Denko, J. S. Yaruss, C. Spotts, L. Davis, A. Davis, P. Fox, P. Soni, M. Blomgren, A. Silverman, G. Riley: Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pagoclon for peRsistent dEvelopmental Stuttering Study. In: Journal of Clinical Psychopharmacology. 30. Jahrgang, Nr. 1, Februar 2010, S. 48–56, doi:10.1097/jcp.0b013e3181caebbe, PMID 20075648.

patents.google.com